Literature DB >> 28060078

Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific Metric.

Yuna Rapoport1, Thomas Freeman, Tatsuki Koyama, Brian G Engelhardt, Madan Jagasia, Bipin N Savani, Uyen Tran, Adetola A Kassim.   

Abstract

PURPOSE: To validate the International Chronic Ocular GVHD Consensus Group (ICCGVHD) diagnostic criteria for chronic ocular chronic graft-versus-host disease (GVHD), by comparing results with comprehensive ophthalmic evaluation after allogeneic hematopoietic stem cell transplantation.
METHODS: A single-institution retrospective chart review was conducted on patients who underwent hematopoietic stem cell transplantation at Vanderbilt University Medical Center in Nashville, TN, from January 1, 2002, through April 17, 2014. A total of 344 patients were eligible for the study. Data collected include the Schirmer test score, corneal fluorescein staining, Ocular Surface Disease Index, conjunctival injection, and presence or absence of systemic GVHD. The diagnosis of chronic ocular GVHD in each participant and determination of the overall severity score were determined based on the newly proposed ICCGVHD diagnostic criteria and compared with the best clinical practice (BCP) score.
RESULTS: Chronic ocular GVHD was diagnosed in 141/344 (41%) participants, of these, 86 (61%) had complete charts. Based on the BCP score, 1.2% had none, 38.4% mild, 47.7% moderate, and 12.8% had severe chronic ocular GVHD. Based on the ICCGVHD, 34.8% had none, 59.3% mild/moderate, and 5.8% had severe chronic ocular GVHD. The clinical diagnostic stages of chronic ocular GVHD by BCP and ICCGVHD criteria had slight agreement (kappa statistic 0.187, with 95% confidence interval 0.049-0.321), with a higher correlation seen in those with severe chronic ocular GVHD.
CONCLUSIONS: The newly proposed ICCGVHD diagnostic criteria can be used reproducibly for the diagnosis and determination of severity of chronic ocular GVHD. However, larger prospective studies are needed to further validate it.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28060078     DOI: 10.1097/ICO.0000000000001109

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  12 in total

1.  Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Authors:  Seungwon An; Ilangovan Raju; Bayasgalan Surenkhuu; Ji-Eun Kwon; Shilpa Gulati; Muge Karaman; Anubhav Pradeep; Satyabrata Sinha; Christine Mun; Sandeep Jain
Journal:  Ocul Surf       Date:  2019-04-06       Impact factor: 5.033

Review 2.  Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

Authors:  Yoshihiro Inamoto; Nuria Valdés-Sanz; Yoko Ogawa; Monica Alves; Luigi Berchicci; John Galvin; Hildegard Greinix; Gregory A Hale; Biljana Horn; Debra Kelly; Hien Liu; Scott Rowley; Helene Schoemans; Ami Shah; Maria Teresa Lupo Stanghellini; Vaibhav Agrawal; Ibrahim Ahmed; Asim Ali; Neel Bhatt; Michael Byrne; Saurabh Chhabra; Zachariah DeFilipp; Kristina Fahnehjelm; Nosha Farhadfar; Erich Horn; Catherine Lee; Sunita Nathan; Olaf Penack; Pinki Prasad; Seth Rotz; Alicia Rovó; Jean Yared; Steven Pavletic; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw; Igor Petriček
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

3.  Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Authors:  Yoshihiro Inamoto; Nuria Valdés-Sanz; Igor Petriček; Yoko Ogawa; Monica Alves; Luigi Berchicci; John Galvin; Hildegard Greinix; Gregory A Hale; Biljana Horn; Debra Kelly; Hien Liu; Scott Rowley; Helene Schoemans; Ami Shah; Maria Teresa Lupo Stanghellini; Vaibhav Agrawal; Ibrahim Ahmed; Asim Ali; Neel Bhatt; Michael Byrne; Saurabh Chhabra; Zack DeFilipp; Kristina Fahnehjelm; Nosha Farhadfar; Erich Horn; Catherine Lee; Sunita Nathan; Olaf Penack; Pinki Prasad; Seth Rotz; Alicia Rovó; Jean Yared; Steven Pavletic; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-12-07       Impact factor: 5.483

4.  Two case reports of continued progression of chronic ocular graft-versus-host disease without concurrent systemic comorbidities treated by amniotic membrane transplantation.

Authors:  Hideto Ikarashi; Naohiko Aketa; Eisuke Shimizu; Yoji Takano; Tetsuya Kawakita; Yuichi Uchino; Yukihiro Matsumoto; Junko Ogawa; Kazuo Tsubota; Yoko Ogawa
Journal:  BMC Ophthalmol       Date:  2021-04-07       Impact factor: 2.209

Review 5.  Update on ocular graft-versus-host disease.

Authors:  Sridevi Nair; Murugesan Vanathi; Ritika Mukhija; Radhika Tandon; Sandeep Jain; Yoko Ogawa
Journal:  Indian J Ophthalmol       Date:  2021-05       Impact factor: 1.848

6.  Ocular Graft-versus-Host Disease Underdiagnosis: A Survey Study.

Authors:  Bradley A Colarusso; Shannon M Bligdon; Allen Y Ganjei; Alan Kwok; Daniel Brocks; Zhonghui K Luo
Journal:  Clin Ophthalmol       Date:  2022-05-03

Review 7.  Beyond dry eye: how co-morbidities influence disease phenotype in dry eye disease.

Authors:  Yonghoon Lee; Minji Kim; Anat Galor
Journal:  Clin Exp Optom       Date:  2021-08-08       Impact factor: 2.742

8.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10

9.  Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation.

Authors:  Meeta Pathak; Phoi Phoi Diep; Xiaoran Lai; Lorentz Brinch; Ellen Ruud; Liv Drolsum
Journal:  Bone Marrow Transplant       Date:  2018-01-30       Impact factor: 5.483

10.  Mesenchymal stem cells (MSC) delays the occurrence of graft-versus-host disease(GVHD) in the inhibition of hematopoietic stem cells in major histocompatibility complex semi-consistent mice by regulating the expression of IFN-γ/IL-6.

Authors:  Ying Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.